Objective and subjective effects of treatment for testicular cancer on sexual function

BJU International

Volumn 84, Issue 6, 1999, Pages 671-678

  Van Basten, J P A ^c   Van Driel, M F ^a   Hoekstra, H J ^a   Sleijfer, D Th ^a   Van De Wiel, H B M ^a   Droste, J H J ^b   Schraffordt Koops, H ^c   Mensink, H J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c NONE

Author keywords

Angiopathy; Chemotherapy; Hormones; Sexual function; Testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; FOLLITROPIN; LUTEINIZING HORMONE; PAPAVERINE; PHENTOLAMINE; SEX HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LEYDIG CELL; LUTEINIZING HORMONE BLOOD LEVEL; MALE; ORCHIECTOMY; PENIS; PENIS ERECTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SEXUAL FUNCTION; TESTIS CANCER; TESTOSTERONE BLOOD LEVEL; VASCULARIZATION;

ADULT; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; IMPOTENCE; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTICULAR NEOPLASMS;

EID: 0032882507     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00262.x     Document Type: Article

References (33)

1. 1 Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777-81
2. 2 Van Basten JPA, Schraffordt Koops H, Sleijfer DTh, Van Driel MF, Hoekstra HJ. Current concepts about testicular cancer. Eur J Surg Oncol 1997; 23: 354-60
3. 3 Osanto S, Bukman A, Van Hock F, Sterk PJ, De laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-9
4. 4 Gietema JA, Sleijfer DTh, Willemse PHB et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-11
5. 5 Sleijfer S, Van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect. Br J Cancer 1995; 71: 120-3
6. 6 Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239-45
7. 7 Van Basten JPA, Jonker-Pool G, Van Driel MF, Sleijfer DTh, Van de Wiel HBM, Hoekstra HJ. The sexual sequelae of testicular cancer. Cancer Treat Rev 1995; 21: 479-95
8. 8 Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer. J Clin Oncol 1997; 15: 1444-8
9. 9 Jonker-Pool G, Van Basten JPA, Hoekstra HJ, Sleijfer DTh, Schraffordt Koops H, Van de Wiel HBM. Sexual functioning after treatment for testicular cancer: a comparison of treatment modalities. Cancer 1997; 80: 454-64
10. 10 Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl Med 1987; 316: 1435-61
11. 11 Brennemann W, Stoffel-Wagner B, Helmers A, Merger J, Jager N, Klingmuller D. Gonadal function of patients treated with cisplatin-based chemotherapy for germ cell cancer. J Urol 1997; 158: 844-50
12. 12 Van Basten JPA, Hoekstra HJ, Van Driel MF et al. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. J Clin Oncol 1997; 79: 363-8
13. 13 Gels ME, Nijboer AP, Hoekstra HJ et al. Complications of post-chemotherapy residual retroperitoneal tumour mass in patients with nonseminomtous testicular germ cell tumours. Br J Urol 1997; 79: 363-8
14. 14 Pratt JJ, Wiegman T, Lappohn RE, Woldring MG. Estimation of plasma testosterone without extraction and chromatography. Clin Chim Acta 1975; 59: 337-46
15. 15 Pratt JJ, Van der Linden G, Doorenbos H, Woldring MG. An improved assay for plasma oestradiol using competitive protein binding. Clin Chim Acta 1974; 50: 137-46
16. 16 Vennix P. The IBCS-thought. Zeist, The Netherlands: NISSO, 1983
17. 17 Weijmar Schultz WCM, Van de Wiel HBM. Sexual functioning after gynaecological cancer treatment. Thesis, State University Groningen, Groningen. The Netherlands, 1991
18. 18 Fossa SD, Haugh E. Sex hormone binding globulin and oestradiol serum levels in patients with testicular cancer. Br J Urol 1990; 66: 533-6
19. 19 Hansen PV, Trykker H, Andersen J. Testicular function in patients with testicular cancer treated with orchidectomy alone or orchidectomy plus cisplatin-based chemotherapy. J Natl Cancer Inst 1989; 81: 1246-50
20. 20 Hoff-Wanderas E, Fossa SD, Heiloo A, Stenwig AE, Norman N. Serum follicle stimulating hormone. Predictor of cancer in the remaining testis in patients with unilateral testicular cancer. Br J Urol 1990; 66: 315-7
21. 21 Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996; 73: 1108-14
22. 22 Hansen SW, Berthelsen JG, Von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8: 1695-8
23. 23 Bancroft J. The Biology of Human Sexuality and its Problems. Edinburgh: Churchill Livingstone, 1989: 12-01
24. 24 Bashin J, Androgen treatment of hypogonadal men. J Clin Endocr Metabol 1992; 74: 1221-5
25. 25 Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and oestradiol on sexual behaviour in normal young men. J Clin Endocr Metabol 1994; 78: 711-6
26. 26 Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snijder SH. Nitric oxide: a physiologic mediator of penile erection. Science 1992; 257: 401-3
27. 27 Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol 1995; 153: 650-2
28. 28 Nijman JM, Schraffordt Koops H, Kremer J, Willemse PHB, Sleijfer DTh, Oldhoff J. Fertility and hormonal function in patients with nonseminomatous tumor of the testis. Arch Androl 1985; 14: 239-46
29. 29 LeBlanc GA, Kantoff PW, Sze-Fong N, Frei E, Waxman DJ. Hormonal pretuberations in patients with testicular cancer treated with cisplatin. Cancer 1992; 69: 2306-10
30. 30 Gooren LJG. Human male sexual functions do not require aromatization of testosterone: a study using tamoxifen, testolactone, and dihydrotestosterone. Arch Sex Behav 1989; 14: 539-48
31. 31 Chapman RM, Sutcliff SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease: a prospective study. JAMA 1980; 254: 1323-8
32. 32 Leitner SP, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 1986; 4: 1500-5
33. 33 Kanno K, Hirata Y, Emori T. Endothelin and Raynaud's phenomenon. Am J Med 1991; 90: 130-2